If you discover you’re pregnant while taking Ozempic, the standard recommendation is to stop the medication immediately and contact your prescriber. Ozempic (semaglutide) is not approved for use during pregnancy, and the FDA labeling advises discontinuing it at least two months before a planned pregnancy due to the drug’s long washout period. That said, the human data collected so far has not shown a clear, consistent increase in birth defects from early exposure, though the evidence remains limited.
This is a situation more people are facing than you might expect. Ozempic and similar medications can restore ovulation in people who previously had irregular cycles, leading to surprise pregnancies. Here’s what the research actually shows about the risks, why the two-month guideline exists, and what to expect if this happens to you.
Why Unplanned Pregnancies on Ozempic Are Common
Ozempic can significantly improve fertility, especially if you have polycystic ovary syndrome (PCOS) or insulin resistance. In one pilot study of people with PCOS and obesity who took semaglutide alongside metformin, 60% achieved pregnancy within the follow-up period. The weight loss itself plays a major role: participants dropped from an average BMI of about 35 to 30 over five months, which can be enough to restart regular ovulation.
If you weren’t ovulating regularly before starting Ozempic, you may not realize your fertility has changed. This is why doctors are increasingly urged to discuss contraception when prescribing these medications to anyone of childbearing age. Hormonal birth control or other reliable methods are important if you’re not planning a pregnancy, because the return of ovulation can happen faster than expected.
What Animal Studies Found
Much of the concern about semaglutide in pregnancy comes from animal research, because controlled studies in pregnant humans aren’t ethical to conduct. The findings in animals were serious enough to warrant strong warnings on the label.
In pregnant rats given semaglutide during the critical window of organ formation, researchers observed fetal deaths, structural abnormalities, and restricted growth. Rabbits and monkeys showed early pregnancy losses and structural problems as well. In both species, the mothers also experienced significant weight loss, making it difficult to separate the drug’s direct effects from the consequences of reduced nutrition.
A study published in the American Journal of Physiology looked more closely at what happens in late pregnancy. Rats treated with semaglutide had fetuses with significantly lower body weight, and this wasn’t simply because the mothers were eating less. The drug reduced the functional area of the placenta and substantially decreased the expression of key nutrient transporters, the proteins responsible for moving glucose and amino acids from mother to fetus. Blood vessel development within the placenta was also impaired. These effects persisted even after the mothers’ blood sugar levels returned to normal, suggesting semaglutide directly interferes with fetal growth through the placenta, independent of blood sugar.
Animal studies don’t always translate directly to humans, and the doses used are often higher relative to body weight. But these results are the primary reason for the precautionary approach.
What Human Data Shows So Far
Human evidence is still thin but growing. A 2025 systematic review pooled five studies covering 1,128 pregnancies with semaglutide exposure. The results were mixed and, importantly, did not identify a clear association with birth defects.
Some individual studies within that review reported complications. One found higher rates of spontaneous abortion and preeclampsia. Another noted preterm births and larger-than-expected babies, but no increase in congenital malformations. A case report described a baby born unusually large (about 11.5 pounds, 38% above expected weight) with shoulder complications during delivery and low blood sugar after birth. That infant developed normally at six months. Researchers speculated the large size may have been linked to rebound weight gain after the mother stopped the medication.
The bottom line from the review: current evidence does not point to a consistent increased risk of major birth defects, but the number of studies is too small and variable to draw firm conclusions. No one can tell you with certainty that early exposure is safe, and no one can tell you it definitely caused harm.
Why the Two-Month Washout Matters
Semaglutide has an unusually long half-life of about 160 hours, or roughly seven days. That means it takes about five weeks for the drug to drop to negligible levels in your body after your last injection. The FDA labeling rounds this up to a two-month buffer before attempting conception, providing a comfortable margin to ensure the medication is fully cleared.
This long persistence in the body is also why discovering a pregnancy a week or two after your last dose is different from discovering one two months later. In the early weeks after stopping, meaningful levels of the drug are still circulating. If you find out you’re pregnant and recently took a dose, the drug will still be active in your system for several more weeks as it gradually clears.
What Happens When You Find Out
The first step is straightforward: stop taking Ozempic and let your prescriber know. Your doctor will likely coordinate with an obstetrician to plan appropriate monitoring for the rest of the pregnancy.
There are a few practical things to be aware of. If you’ve been losing weight on the medication, your caloric intake may have been lower than what’s ideal for early fetal development. Once you stop the drug, your appetite will likely return, and your doctor may want to discuss nutrition to make sure you’re getting adequate calories, protein, and micronutrients during a critical growth window.
Some people experience rebound weight gain after stopping semaglutide, sometimes rapidly. This is normal and expected as the appetite-suppressing effects wear off. In pregnancy, some weight gain is healthy and necessary, but the pace and amount may need monitoring, particularly because one case report linked post-discontinuation rebound to an unusually large baby.
Blood sugar management also changes. If you were taking Ozempic for type 2 diabetes, you’ll need a different approach to blood sugar control during pregnancy. Poorly controlled blood sugar carries its own serious risks, including preeclampsia, preterm delivery, and complications for the baby. Your medical team will transition you to pregnancy-safe options for glucose management.
Putting the Risk in Perspective
The animal data is concerning. The human data is reassuring but incomplete. If you’re reading this because you just found out you’re pregnant while on Ozempic, the most honest answer is that the limited human evidence collected so far has not confirmed the worst-case scenarios seen in animals. Many people exposed to semaglutide in early pregnancy have gone on to deliver healthy babies. But “no consistent increased risk detected yet” is not the same as “proven safe,” and larger studies are still needed.
What you can control now is stopping the medication, getting into prenatal care early, and making sure your nutrition and blood sugar are well managed going forward. The timing of your last dose, how far along you are, and your individual health profile all factor into what monitoring makes sense, which is something your medical team can tailor to your situation.